Phase 1 open label, dose escalating, multiple dose study to determine the safety, tolerability, maximum tolerated dose, and pharmacokinetics of MPC-2130 administered as daily IV infusions for 5 days, in patients with refractory cancer.

Trial Profile

Phase 1 open label, dose escalating, multiple dose study to determine the safety, tolerability, maximum tolerated dose, and pharmacokinetics of MPC-2130 administered as daily IV infusions for 5 days, in patients with refractory cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2009

At a glance

  • Drugs MPC 2130 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Oct 2009 Actual number of patients (8) added as reported by ClinicalTrials.gov record.
    • 27 Oct 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 30 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top